The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2’deoxycytidine (decitabine) are differentially regulated by cell cycle progression
暂无分享,去创建一个
W. Samlowski | F. Fitzpatrick | Amanda L. Alexander | Mazin A Al-Salihi | Margaret Yu | David M. Burnett
[1] Pan‐Chyr Yang,et al. Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. , 2010, Cancer research.
[2] B. Ramsahoye,et al. Targeting of 5-aza-2′-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme , 2010, Nucleic acids research.
[3] J. Issa,et al. Targeting DNA Methylation , 2009, Clinical Cancer Research.
[4] I. Wistuba,et al. Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas , 2009, Clinical Cancer Research.
[5] David A Jones,et al. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. , 2008, Cancer research.
[6] Andreas Schätzlein,et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] H. Leonhardt,et al. Dynamics of Dnmt1 interaction with the replication machinery and its role in postreplicative maintenance of DNA methylation , 2007, Nucleic acids research.
[8] W. Deppert,et al. Transcription-independent pro-apoptotic functions of p53. , 2005, Current opinion in cell biology.
[9] M. Ljungman. Activation of DNA damage signaling. , 2005, Mutation research.
[10] H. Leonhardt,et al. Recruitment of DNA methyltransferase I to DNA repair sites. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[11] David A Jones,et al. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] K. Ghoshal,et al. 5-Aza-Deoxycytidine Induces Selective Degradation of DNA Methyltransferase 1 by a Proteasomal Pathway That Requires the KEN Box, Bromo-Adjacent Homology Domain, and Nuclear Localization Signal , 2005, Molecular and Cellular Biology.
[13] S. Pradhan,et al. Human maintenance DNA (cytosine-5)-methyltransferase and p53 modulate expression of p53-repressed promoters. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[14] H. Leonhardt,et al. Replication‐independent chromatin loading of Dnmt1 during G2 and M phases , 2004, EMBO reports.
[15] Albert Jeltsch,et al. The Dnmt1 DNA-(cytosine-C5)-methyltransferase Methylates DNA Processively with High Preference for Hemimethylated Target Sites* , 2004, Journal of Biological Chemistry.
[16] H. Komori,et al. Differential regulation of expression of the mammalian DNA repair genes by growth stimulation , 2004, Oncogene.
[17] Jorge Cortes,et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. , 2004, Blood.
[18] W. Schulz,et al. Decrease of DNA methyltransferase 1 expression relative to cell proliferation in transitional cell carcinoma , 2003, International journal of cancer.
[19] P. Laird,et al. Phase I trial of continuous infusion 5-aza-2′-deoxycytidine , 2003, Cancer Chemotherapy and Pharmacology.
[20] M. O’Reilly,et al. Growth arrest in G1 protects against oxygen‐induced DNA damage and cell death , 2002, Journal of cellular physiology.
[21] David A Jones,et al. Reactivating the expression of methylation silenced genes in human cancer , 2002, Oncogene.
[22] Peter A. Jones,et al. Cell division is required for de novo methylation of CpG islands in bladder cancer cells. , 2002, Cancer research.
[23] Y. Seo,et al. p53 regulation of DNA excision repair pathways. , 2002, Mutagenesis.
[24] Keith D Robertson,et al. DNA methylation, methyltransferases, and cancer , 2001, Oncogene.
[25] D. Jones,et al. Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine. , 2001, Molecular pharmacology.
[26] Samuel H. Wilson,et al. A role for p53 in base excision repair , 2001, The EMBO journal.
[27] F. Ishikawa,et al. MBD2‐MBD3 complex binds to hemi‐methylated DNA and forms a complex containing DNMT1 at the replication foci in late S phase , 2000, Genes to cells : devoted to molecular & cellular mechanisms.
[28] K. Robertson,et al. Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G(0)/G(1) to S phase transition in normal and tumor cells. , 2000, Nucleic acids research.
[29] M. Lübbert,et al. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Peter A. Jones,et al. Roles of Cell Division and Gene Transcription in the Methylation of CpG Islands , 1999, Molecular and Cellular Biology.
[31] K. Kinzler,et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. , 1999, The Journal of clinical investigation.
[32] G. Wahl,et al. ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage , 1998, Current Biology.
[33] R. Jaenisch,et al. Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[34] D. Santi,et al. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[35] R. Snyder. Inhibitors of ribonucleotide reductase alter DNA repair in human fibroblasts through specific depletion of purine deoxynucleotide triphosphates , 1984, Cell Biology and Toxicology.
[36] J. Christman,et al. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. , 1982, The Journal of biological chemistry.
[37] Peter A. Jones,et al. Epigenetics in cancer. , 2010, Carcinogenesis.
[38] Matthew Tudor,et al. Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation , 2001, Nature Genetics.
[39] S. Peller. Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response. , 1998, Seminars in cancer biology.